Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 2
1969 1
1971 1
1972 2
1973 1
1976 1
1977 1
1979 1
1980 1
1984 1
1985 4
1987 1
1988 2
1989 2
1990 1
1991 2
1992 1
1993 3
1994 4
1995 3
1996 6
1997 5
1998 4
1999 2
2000 6
2001 15
2002 14
2003 20
2004 18
2005 18
2006 23
2007 29
2008 53
2009 39
2010 45
2011 76
2012 96
2013 94
2014 105
2015 167
2016 173
2017 162
2018 200
2019 226
2020 257
2021 308
2022 362
2023 174

Text availability

Article attribute

Article type

Publication date

Search Results

2,425 results

Results by year

Filters applied: . Clear all
Page 1
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. Camidge DR, et al. Among authors: niu h. J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16. J Thorac Oncol. 2021. PMID: 34537440 Free article. Clinical Trial.
Gospel of malignant Glioma: Oncolytic virus therapy.
Li J, Meng Q, Zhou X, Zhao H, Wang K, Niu H, Wang Y. Li J, et al. Among authors: niu h. Gene. 2022 Apr 15;818:146217. doi: 10.1016/j.gene.2022.146217. Epub 2022 Jan 28. Gene. 2022. PMID: 35093451 Review.
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
Ou SI, Nishio M, Ahn MJ, Mok T, Barlesi F, Zhou C, Felip E, de Marinis F, Kim SW, Pérol M, Liu G, Migliorino MR, Kim DW, Novello S, Bearz A, Garrido P, Mazieres J, Morabito A, Lin HM, Yang H, Niu H, Zhang P, Kim ES. Ou SI, et al. Among authors: niu h. J Thorac Oncol. 2022 Dec;17(12):1404-1414. doi: 10.1016/j.jtho.2022.08.018. Epub 2022 Sep 10. J Thorac Oncol. 2022. PMID: 36096442 Free article.
Lupus gut microbiota transplants cause autoimmunity and inflammation.
Ma Y, Guo R, Sun Y, Li X, He L, Li Z, Silverman GJ, Chen G, Gao F, Yuan J, Wei Q, Li M, Lu L, Niu H. Ma Y, et al. Among authors: niu h. Clin Immunol. 2021 Dec;233:108892. doi: 10.1016/j.clim.2021.108892. Epub 2021 Nov 20. Clin Immunol. 2021. PMID: 34813937
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).
Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, Sun JH, Jin ZC, Chen JJ, Ge NJ, Ding WB, Li WH, Huang JH, Mu W, Gu SZ, Li JP, Zhao H, Wen SW, Lei YM, Song YS, Yuan CW, Wang WD, Huang M, Zhao W, Wu JB, Wang S, Zhu X, Han JJ, Ren WX, Lu ZM, Xing WG, Fan Y, Lin HL, Zhang ZS, Xu GH, Hu WH, Tu Q, Su HY, Zheng CS, Chen Y, Zhao XY, Fang ZT, Wang Q, Zhao JW, Xu AB, Xu J, Wu QH, Niu HZ, Wang J, Dai F, Feng DP, Li QD, Shi RS, Li JR, Yang G, Shi HB, Ji JS, Liu YE, Cai Z, Yang P, Zhao Y, Zhu XL, Lu LG, Teng GJ; CHANCE001 Investigators. Zhu HD, et al. Among authors: niu hz. Signal Transduct Target Ther. 2023 Feb 8;8(1):58. doi: 10.1038/s41392-022-01235-0. Signal Transduct Target Ther. 2023. PMID: 36750721 Free PMC article.
Editorial: The Brain Under Fatigue.
Niu H, Ming D, Papadelis C, Alexandrakis G. Niu H, et al. Front Neurosci. 2022 Jun 3;16:945527. doi: 10.3389/fnins.2022.945527. eCollection 2022. Front Neurosci. 2022. PMID: 35720699 Free PMC article. No abstract available.
2,425 results